290 related articles for article (PubMed ID: 10819531)
21. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
Santarosa M; Dolcetti R; Magri MD; Crivellari D; Tibiletti MG; Gallo A; Tumolo S; Della Puppa L; Furlan D; Boiocchi M; Viel A
Int J Cancer; 1999 Sep; 83(1):5-9. PubMed ID: 10449599
[TBL] [Abstract][Full Text] [Related]
22. The glittering prize.
Nat Genet; 1994 Oct; 8(2):105-6. PubMed ID: 7842002
[No Abstract] [Full Text] [Related]
23. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
Yazici H; Bitisik O; Akisik E; Cabioglu N; Saip P; Muslumanoglu M; Glendon G; Bengisu E; Ozbilen S; Dincer M; Turkmen S; Andrulis IL; Dalay N; Ozcelik H
Br J Cancer; 2000 Sep; 83(6):737-42. PubMed ID: 10952777
[TBL] [Abstract][Full Text] [Related]
24. The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2.
Peelen T; Cornelis RS; van Vliet M; Petrij-Bosch A; Cleton-Jansen AM; Meijers-Heijboer H; Klijn JG; Vasen HF; Cornelisse CJ; Devilee P
Eur J Hum Genet; 1996; 4(4):225-30. PubMed ID: 8875189
[TBL] [Abstract][Full Text] [Related]
25. Allelic imbalance on chromosomes 13 and 17 and mutation analysis of BRCA1 and BRCA2 genes in monozygotic twins concordant for breast cancer.
Försti A; Luo L; Vorechovsky I; Söderberg M; Lichtenstein P; Hemminki K
Carcinogenesis; 2001 Jan; 22(1):27-33. PubMed ID: 11159737
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and prostate cancer.
Rosen EM; Fan S; Goldberg ID
Cancer Invest; 2001; 19(4):396-412. PubMed ID: 11405179
[TBL] [Abstract][Full Text] [Related]
27. Multiplying functions for BRCA1 and BRCA2?. Meeting report, The Breakthrough Breast Cancer Second International Workshop on the function of BRCA1 and BRCA2, Cambridge, UK, 9-10 September 1999.
Venkitaraman AR
Biochim Biophys Acta; 2000 May; 1470(3):R41-7. PubMed ID: 10799749
[No Abstract] [Full Text] [Related]
28. Inherited predisposition to breast cancer.
Ponder BA
Biochem Soc Symp; 1998; 63():223-30. PubMed ID: 9513726
[TBL] [Abstract][Full Text] [Related]
29. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
30. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
Schubert EL; Mefford HC; Dann JL; Argonza RH; Hull J; King MC
Genet Test; 1997; 1(1):41-6. PubMed ID: 10464624
[TBL] [Abstract][Full Text] [Related]
31. A second breast cancer susceptibility gene is found.
Marx J
Science; 1996 Jan; 271(5245):30-1. PubMed ID: 8539592
[No Abstract] [Full Text] [Related]
32. [BRCA1 and BRCA2--breast cancer susceptibility genes].
Dagan E; Gershoni-Baruch R
Harefuah; 1997 Nov; 133(10):455-7. PubMed ID: 9418320
[No Abstract] [Full Text] [Related]
33. [BRCA1 and BRCA2: mutations and other genetic changes--practical relevance].
Scherneck S; Hofmann W
Chirurg; 1999 Apr; 70(4):373-9. PubMed ID: 10354832
[TBL] [Abstract][Full Text] [Related]
34. A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.
Arason A; Jonasdottir A; Barkardottir RB; Bergthorsson JT; Teare MD; Easton DF; Egilsson V
J Med Genet; 1998 Jun; 35(6):446-9. PubMed ID: 9643283
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 and BRCA2.
Bertwistle D; Ashworth A
Curr Biol; 2000 Aug; 10(16):R582. PubMed ID: 10985371
[No Abstract] [Full Text] [Related]
36. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
37. Testing for inherited susceptibility to breast and ovarian cancer.
Brunner HG; Ligtenberg MJ
Eur J Obstet Gynecol Reprod Biol; 1999 Feb; 82(2):143-6. PubMed ID: 10206405
[No Abstract] [Full Text] [Related]
38. Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors.
Tong D; Kucera E; Schuster E; Schmutzler RK; Swoboda H; Reinthaller A; Leodolter S; Zeillinger R
Int J Cancer; 2000 Oct; 88(2):319-22. PubMed ID: 11004687
[No Abstract] [Full Text] [Related]
39. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
Van Der Looij M; Szabo C; Besznyak I; Liszka G; Csokay B; Pulay T; Toth J; Devilee P; King MC; Olah E
Int J Cancer; 2000 Jun; 86(5):737-40. PubMed ID: 10797299
[TBL] [Abstract][Full Text] [Related]
40. Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
Claes K; Machackova E; De Vos M; Mortier G; De Paepe A; Messiaen L
Hum Mutat; 1999; 13(3):256. PubMed ID: 10090482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
